Q32 Bio (QTTB) Income from Continuing Operations (2017 - 2026)
Q32 Bio (QTTB) posted quarterly Income from Continuing Operations of 16087000.0 for Q1 2026, down 45.83% year-over-year from 29699698.24 in Q1 2025, and down 127.87% quarter-over-quarter from 57730000.0 in Q4 2025.
Q32 Bio (QTTB) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Q32 Bio's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 16087000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 45.83% year-over-year to 16087000.0; the TTM figure through Mar 2026 stood at 24765000.0 (up 142.45% YoY), while the FY2025 annual figure was 29821000.0, up 164.68% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 16087000.0, down from 57730000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 92696000.0 in Q1 2022, with the low at 34555000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 13966000.0 (2023), against an average of 5150176.47.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations soared 8738.96% in 2022, then slumped 1015.44% in 2025.
- Q32 Bio's Income from Continuing Operations stood at 34555000.0 in 2022, then gained by 21.48% to 27132000.0 in 2023, then surged by 47.7% to 14189000.0 in 2024, then surged by 506.86% to 57730000.0 in 2025, then sank by 127.87% to 16087000.0 in 2026.
- Business Quant data shows QTTB's Income from Continuing Operations at 16087000.0 in Q1 2026, 57730000.0 in Q4 2025, and 7389000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | -30.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.73 Mn |
| Mar 31, 2026 | -16.09 Mn |
| Dec 31, 2025 | 57.73 Mn |
| Sep 30, 2025 | -7.39 Mn |
| Jun 30, 2025 | -9.49 Mn |
| Mar 31, 2025 | -11.03 Mn |
| Dec 31, 2024 | -14.19 Mn |
| Sep 30, 2024 | -17.60 Mn |
| Jun 30, 2024 | -15.53 Mn |
| Mar 31, 2024 | 1.21 Mn |
| Dec 31, 2023 | -27.13 Mn |
| Sep 30, 2023 | -13.97 Mn |
| Jun 30, 2023 | -5.81 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | -34.56 Mn |
| Sep 30, 2022 | -31.64 Mn |
| Jun 30, 2022 | -27.94 Mn |
| Mar 31, 2022 | 92.70 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -30.61 Mn |